This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/pubchem-compound/
n21http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/iuphar/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/chemspider/
n19http://linked.opendata.cz/ontology/sukl/drug/
n20http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00508/identifier/chebi/

Statements

Subject Item
n2:DB00508
rdf:type
n4:Drug
n4:description
A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem]
n4:group
approved
n4:indication
Used mainly in the management of psychoses. Also used to control nausea and vomiting.
owl:sameAs
n16:DB00508 n21:DB00508
dcterms:title
Triflupromazine
adms:identifier
n7:Triflupromazine n8:5568 n9:46507344 n10:5367 n11:DB00508 n12:9711 n13:D00390 n14:PA451773 n17:4330 n18:4330
n4:mechanismOfAction
Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT<sub>2B</sub>).
n4:synonym
Triflupromazine 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine Triflupromazinum Fluopromazine Triflupromazina Triflupromazin 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine 2-(Trifluoromethyl)promazine
n4:toxicity
Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
n4:proteinBinding
Very high (90% or more).
n4:salt
n4:IUPAC-Name
n5:271B622C-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B6232-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B6231-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B622E-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B622F-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B6230-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B622A-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B6228-363D-11E5-9242-09173F13E4C5 n5:271B622B-363D-11E5-9242-09173F13E4C5 n5:271B6241-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B6229-363D-11E5-9242-09173F13E4C5 n5:271B6242-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:N05AA05
n4:H-Bond-Acceptor-Count
n5:271B6238-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B6239-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B6233-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B6234-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B6236-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B6235-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B6237-363D-11E5-9242-09173F13E4C5
n4:absorption
Absorption may be erratic and peak plasma concentrations show large interindividual differences.
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
146-54-3
n4:category
n4:Bioavailability
n5:271B623D-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B623F-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B6240-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B623C-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B623B-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B623E-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B622D-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B623A-363D-11E5-9242-09173F13E4C5